D'AVOLIO, Antonio
D'AVOLIO, Antonio
SCIENZE MEDICHE
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop
2014-01-01 A. De Nicolò; A. Ciancio; L. Boglione; A. Mohamed Abdi; A. Smedile; G.P. Caviglia; G. DI Perri; M. Rizzetto; A. D'Avolio
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load
2010-01-01 Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G.
A multidisciplinary pilot study in people with HIV who switched from triple to dual therapy: influence on physical capacities, lifestyle and oxidative stress
2024-01-01 Anna Mulasso, Jessica Cusato, Simone Cuomo, Stefano Laspia, Barbara Mercadante, Elena Turiano, Francesco Chiara, Jacopo Mula, Alice Palermiti, Alessandra Manca, Luca Beratto, Paolo Riccardo Brustio, Corrado Lupo, Antonio D'Avolio, Alberto Rainoldi
A new HPLC method to measure plasma levels of enfuvirtide (ENF or T-20)
2004-01-01 D'Avolio A.; Sciandra M.; Bonora S.; Ibanez A.; Marucco D.; Di Perri G.
A new UPLC-MS-MS method to quantify first line antituberculosis agents in plasma spotted on dried sample spots device (DSSD)
2015-01-01 L. Baietto; V. Poretti; K. Baruffi; G. Di Perri; A. D'Avolio
A new validated Solid Phase Extraction (SPE)-HPLC method to measure plasma concentrations of tenofovir
2004-01-01 D'Avolio A.; Sciandra M.; Bonora S.; Boffito M.; Canta F.; De Requena D.; Di Perri G.
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients.
2008-01-01 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance
2009-01-01 Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A
A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance
2010-01-01 Schipani A; Siccardi M; Boffito M; D’Avolio A; Bonora S; Davies G; Khoo S; Back D; Di Perri G; Owen A
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect"
2016-01-01 D'Avolio, A.; Ariaudo, A.; Favata, F.; De Nicolò, A.; Simiele, M.; Boglione, L.; Carcieri, C.; Di Perri, G.
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells
2016-01-01 Pensi, D.; De Nicolò, A.; Favata, F.; Pisciotta, C.; Di Perri, G.; D'Avolio, A.
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina
2009-01-01 Antonio D'Avolio; Marco Siccardi; Deborah Gatti; Lorena Baietto; Francesca Romana Stefani; Marco Simiele; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples
2014-01-01 Pensi D; De Nicolò A; Pinon M; Calvo PL; Di Perri G; D'Avolio A
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
2010-01-01 Bonora S; Calcagno A; Viganò O; Bigliano P; Rusconi S; Trentini L; Tettoni MC; Orofino G; Salassa B; Bramato C; D'Avolio A; Siccardi M; Colella E; Galli M; Di Perri G
Anidulafungin pharmacokinetic evaluation in a cohort of patients
2011-01-01 F.G. De Rosa; L. Baietto; A. D’Avolio; D. Pasero; S. Raviolo; S. Pace; C. Marra; V.M. Ranieri; G. Di Perri
Antibiotic diffusion in pseudoarthrosic infected bone: glycopeptides, fluoroquinolones and carbapenems
2007-01-01 S. Garazzino; A. Aprato; D. Aloj; F.G. De Rosa; A. D'Avolio; A. Massé; G. Di Perri
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study
2017-01-01 De Nicolò, A.; Boglione, L.; Carcieri, C.; Cusato, J.; Mornese Pinna, S.; Favata, F.; Ariaudo, A.; Di Perri, G.; D’Avolio, A.
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination
2010-01-01 Marco Simiele; Antonio D’Avolio; Marco Siccardi; Lorena Baietto; Francesca Romana Stefani; Silvia Agati; Jessica Cusato; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri
ASSORBENTI IGIENICI: SINTOMATOLOGIA ED ISOLAMENTI MICROBIOLOGICI
2003-01-01 Audisio G.; Amarù G.; D'Avolio A.; Orso Giacone G.; Properzi C.
Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
2012-01-01 Brizzi MP; Fazio N; Ferrero A; Nobili E; Volante M; Tozzi L; D'Avolio A; Milanesi E; Dogliotti L; Berruti A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop | 2014 | A. De Nicolò; A. Ciancio; L. Boglione; A. Mohamed Abdi; A. Smedile; G.P. Caviglia; G. DI Perri; M. Rizzetto; A. D'Avolio | |
| A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load | 2010 | Calcagno A; Milia MG; D'Avolio A; Ndayishimiyae P; Dusabimana P; Bonora S; Cusato J; Simiele M; Rostagno R; Siccardi M; Audagnotto S; Ghisetti V; Di Perri G. | |
| A multidisciplinary pilot study in people with HIV who switched from triple to dual therapy: influence on physical capacities, lifestyle and oxidative stress | 2024 | Anna Mulasso, Jessica Cusato, Simone Cuomo, Stefano Laspia, Barbara Mercadante, Elena Turiano, Francesco Chiara, Jacopo Mula, Alice Palermiti, Alessandra Manca, Luca Beratto, Paolo Riccardo Brustio, Corrado Lupo, Antonio D'Avolio, Alberto Rainoldi | |
| A new HPLC method to measure plasma levels of enfuvirtide (ENF or T-20) | 2004 | D'Avolio A.; Sciandra M.; Bonora S.; Ibanez A.; Marucco D.; Di Perri G. | |
| A new UPLC-MS-MS method to quantify first line antituberculosis agents in plasma spotted on dried sample spots device (DSSD) | 2015 | L. Baietto; V. Poretti; K. Baruffi; G. Di Perri; A. D'Avolio | |
| A new validated Solid Phase Extraction (SPE)-HPLC method to measure plasma concentrations of tenofovir | 2004 | D'Avolio A.; Sciandra M.; Bonora S.; Boffito M.; Canta F.; De Requena D.; Di Perri G. | |
| A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. | 2008 | Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G. | |
| A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance | 2009 | Schipani A; Siccardi M; D'Avolio A; Baietto L; Calcagno A; Tettoni C; Bonora S; Davis G; Khoo S; Back DJ; Di Perri G; Owen A | |
| A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance | 2010 | Schipani A; Siccardi M; Boffito M; D’Avolio A; Bonora S; Davies G; Khoo S; Back D; Di Perri G; Owen A | |
| A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" | 2016 | D'Avolio, A.; Ariaudo, A.; Favata, F.; De Nicolò, A.; Simiele, M.; Boglione, L.; Carcieri, C.; Di Perri, G. | |
| A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells | 2016 | Pensi, D.; De Nicolò, A.; Favata, F.; Pisciotta, C.; Di Perri, G.; D'Avolio, A. | |
| ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina | 2009 | Antonio D'Avolio; Marco Siccardi; Deborah Gatti; Lorena Baietto; Francesca Romana Stefani; Marco Simiele; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri | |
| An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples | 2014 | Pensi D; De Nicolò A; Pinon M; Calvo PL; Di Perri G; D'Avolio A | |
| Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting | 2010 | Bonora S; Calcagno A; Viganò O; Bigliano P; Rusconi S; Trentini L; Tettoni MC; Orofino G; Salassa B; Bramato C; D'Avolio A; Siccardi M; Colella E; Galli M; Di Perri G | |
| Anidulafungin pharmacokinetic evaluation in a cohort of patients | 2011 | F.G. De Rosa; L. Baietto; A. D’Avolio; D. Pasero; S. Raviolo; S. Pace; C. Marra; V.M. Ranieri; G. Di Perri | |
| Antibiotic diffusion in pseudoarthrosic infected bone: glycopeptides, fluoroquinolones and carbapenems | 2007 | S. Garazzino; A. Aprato; D. Aloj; F.G. De Rosa; A. D'Avolio; A. Massé; G. Di Perri | |
| Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study | 2017 | De Nicolò, A.; Boglione, L.; Carcieri, C.; Cusato, J.; Mornese Pinna, S.; Favata, F.; Ariaudo, A.; Di Perri, G.; D’Avolio, A. | |
| Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination | 2010 | Marco Simiele; Antonio D’Avolio; Marco Siccardi; Lorena Baietto; Francesca Romana Stefani; Silvia Agati; Jessica Cusato; Mauro Sciandra; Stefano Bonora; Giovanni Di Perri | |
| ASSORBENTI IGIENICI: SINTOMATOLOGIA ED ISOLAMENTI MICROBIOLOGICI | 2003 | Audisio G.; Amarù G.; D'Avolio A.; Orso Giacone G.; Properzi C. | |
| Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study | 2012 | Brizzi MP; Fazio N; Ferrero A; Nobili E; Volante M; Tozzi L; D'Avolio A; Milanesi E; Dogliotti L; Berruti A |